Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today’s medicine can only offer symptom management at best. Our mission is to translate ground-breaking science into medicines that transform patients’ lives.
We are passionate about our science and driven by the purpose it serves. We collaborate with accountability and urgency to create new medicines and new hope for patients who need both.
Sangamo is one of the few companies pursuing programs across the spectrum of genomic medicine. Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations.
Each step toward the possibility of eliminating the need for frequent, life-long treatment for the patients and families affected by debilitating disease is exciting. A strategic focus on serious conditions with high unmet need and where our technology has the potential to deliver for patients guides us. Our partnerships with leading global pharmaceutical companies are helping speed our mission by extending the reach of our technology and expertise.
Our investment in world-class manufacturing capabilities gives us the advantage of greater control over timelines, quality and supply for our robust pipeline.
We have a state-of-the-art cGMP AAV manufacturing facility and trusted CDMO partner that together will support Sangamo’s diverse pipeline now, and in the future.